<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Because of marrow <z:mp ids='MP_0003045'>fibrosis</z:mp>, bone marrow <z:hpo ids='HP_0002835'>aspirations</z:hpo> are often nonconclusive in patients with hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (HCL) </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, histologic examination is important in HCL but often difficult in cases with low numbers of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>A combined immunohistochemical positivity for <z:chebi fb="28" ids="35299">DBA</z:chebi>.44 and <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi>-resistant phosphatase was previously found in 100% of HCL and suggested to be specific for this diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>To further assess the diagnostic specificity and sensitivity of this immunohistochemical approach in a higher number of cases, we analyzed 56 HCLs and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> tissue microarrays, including 840 cases of the most frequent non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> HCLs showed combined positivity for these two proteins (100% sensitivity) </plain></SENT>
<SENT sid="5" pm="."><plain>Both antibodies were often positive in other <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="28" ids="35299">DBA</z:chebi>.44 reactivity was especially frequent in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (46%), whereas <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi>-resistant acid phosphatase (TRAP) expression was often seen in mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (57%), primary mediastinal large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (54%), and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (41%) </plain></SENT>
<SENT sid="7" pm="."><plain>A combined <z:chebi fb="28" ids="35299">DBA</z:chebi>.44/TRAP positivity was seen in only 3% of non-HCL non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphatic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Overall, these data confirm the utility of combined immunohistochemical <z:chebi fb="28" ids="35299">DBA</z:chebi>.44/TRAP expression analysis in confirming the diagnosis of HCL </plain></SENT>
<SENT sid="9" pm="."><plain>However, combined positivity for these markers is highly sensitive but not absolutely specific for HCL </plain></SENT>
</text></document>